{
    "doi": "https://doi.org/10.1182/blood.V104.11.1373.1373",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=24",
    "start_url_page_num": 24,
    "is_scraped": "1",
    "article_title": "Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL). ",
    "article_date": "November 16, 2004",
    "session_type": "Poster Sessions",
    "topics": [
        "bcl2 gene",
        "cancer",
        "carrying",
        "follicular lymphoma",
        "idiopathic guttate hypomelanosis",
        "immunoglobulin heavy chains",
        "lymphoma",
        "polymerase chain reaction",
        "follow-up",
        "blood tests"
    ],
    "author_names": [
        "Marco Ladetto, MD",
        "Barbara Mantoan, PhD",
        "Federica De Marco, MD",
        "Berardino Pollio, MD",
        "Daniela Drandi, PhD",
        "Irene Ricca, MD",
        "Sonia Vallet, MD",
        "Mara Compagno, PhD",
        "Monica Astolfi, PhD",
        "Maria Dell\u2019Aquila, PhD",
        "Roberto Francese, PhD",
        "Gloria Pagliano, PhD",
        "Luigia Monitillo, PhD",
        "Giacomo Tamponi, MD",
        "Mario Boccadoro, MD",
        "Corrado Tarella, MD"
    ],
    "author_affiliations": [
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ],
        [
            "Divisione di Ematologia - Dipartimento di Medicina ed Oncologia Sperimentale, Universita\u2019 di Torino - Azienda Ospedaliera S. Giovanni Battista, Torino, Italy."
        ]
    ],
    "first_author_latitude": "45.05406275",
    "first_author_longitude": "7.676927349999999",
    "abstract_text": "Introduction: NLABRs are frequently observed in cancer free-subjects. We recently observed that NLABR-positive clones can persist up to 60 days (Ladetto et al, J Clin Oncol 2003). However the long-term kinetics and potential pre-neoplastic role of NLABR-carrying cells are unknown. To define the natural history of NLABR-positive clones, long term monitoring of cancer-free subjects carrying these lesions has been performed. Methods: 118 subjects undergoing periodical blood examinations for warfarin therapy were screened for the bcl-2/IgH translocation. PCR-positive subjects underwent subsequent monitoring at least once every three months. NLABR-positive clones were monitored using both nested and real time-PCR according to previously published approaches (Ladetto et al Exp Hematol 2001). Sequence homology of NLABRs has always been confirmed by direct sequencing of nested PCR products. Results: 15 NLABR-positive subjects were identified out of 118 (12.7%) subjects. NLABR-positive subjects were monitored for a median time of 13 months (mos) (range 3\u201330 mos) for a total number of 60 timepoints. In eight subjects (53%), NLABRs detected at study initiation were not detected again in follow-up samples. These eight subjects have been monitored for median period of 12 mos (range 3\u201328 mos). Follow-up samples in this group were usually PCR-negative, although transient PCR-positivity due to unrelated NLABRs were noticed in two samples. In seven subjects (47%), the same NLABR observed at study initiation was detected one or more times at follow-up. In four subjects, NLABRs detected at diagnosis were amplified in every available follow-up sample (three to seven samples were available for each subject). In three, NLABRs detected at diagnosis were amplified only in a fraction of follow-up samples while the remaining were PCR-negative. Overall, persistent NLABRs were followed on these subjects for a median time of 15 months (range 3\u201330). The median burden of persistent NLABRs assessed by real-time PCR was 33 rearrangements (rg)/10 6 diploid genomes (dg) (range <10\u2013760), while the median burden of short-lived NLABRs was <10rg/10 6 dg (range <10\u2013330). The number of NLABR-positive cells appeared to be rather stable in subjects with persistent NLABR-positive clones. In none of these subjects we could detect differences greater than 1 log among available follow-up samples. Subjects having mixed PCR-positive and PCR-negative results had a smaller tumor burden compared to those constantly PCR-positive. This is consistent with the presence of a small though persistent clonal population. Studies on selected populations showed that NLABR-positive cells were CD19-positive. Discussion: NLABR-positive clones are long-lived cell populations in approximately 50% of cases. Based on this finding it is reasonable to hypothesize the existence of a follicular lymphoma (FL)-related lymphoproliferation of undetermined significance. Since NLABRs occurs in more than than 10% of healthy subjects, this condition is expected to be highly prevalent in the general population (as observed in MGUS and CLUS) and of potential relevance for the pathogenesis of FL."
}